Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Mucosal Immunol. 2015 Mar 11;8(6):1237–1247. doi: 10.1038/mi.2015.14

Figure 7. MyD88-dependence of the adjuvant effects of pulmonary beryllium exposure.

Figure 7

A. Total number (mean ± SEM) of AF647-ova+ cDCs in WT B6 (black circles) or MyD88KO mice (gray squares) treated i.t with AF647-ova + Be(OH)2 (filled symbols) or AF647-ova (open triangles) is shown at indicated time points from a representative experiment of 2 (n = 4 mice per group). B. CD80 (left panels) and CD86 (right panels) expression (geometric MFI) is shown on gated AF647-ova+ CD11b+ and CD103+ cDC subsets derived from AF647-ova + Be(OH)2-treated WT B6 mice (black circles), AF647-ova + Be(OH)2-treated MyD88KO mice (gray squares) and AF647-ova-treated WT B6 mice (open triangles) is shown. Data are from a representative experiment of 2 (n = 4 mice per group). C. Total number (mean ± SEM) of 3K-specific CD4+ T cells in the LDLNs on day 12 of the primary response in WT B6 and MyD88KO mice treated with 3K-ova ± Be(OH)2 is shown. Data is combined from 3 separate experiments (n = 4 mice per group in each experiment). In A and B, a t-test was used to determine differences between WT and MyD88KO mice treated with AF647-ova + Be(OH)2 at each time point, and a one-way ANOVA was used to determine differences between groups in C. Significance levels are indicated by asterisks (* p < 0.05, ** p < 0.01, *** p < 0.001).